Gregory Fraser
Stock Analyst at Truist Securities
(3.35)
# 1,013
Out of 4,734 analysts
34
Total ratings
53.85%
Success rate
16.38%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Hold | $60 → $62 | $58.46 | +6.06% | 8 | Oct 22, 2024 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $7.44 | -5.91% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.42 | +1,816.17% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $5.64 | +59.57% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $8.26 | -15.25% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $55.31 | -47.57% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $26.17 | +263.01% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $10.51 | +71.27% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $12.68 | +215.46% | 2 | May 26, 2023 |
ANI Pharmaceuticals
Oct 22, 2024
Maintains: Hold
Price Target: $60 → $62
Current: $58.46
Upside: +6.06%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $7.44
Upside: -5.91%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.42
Upside: +1,816.17%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $5.64
Upside: +59.57%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $8.26
Upside: -15.25%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $55.31
Upside: -47.57%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $26.17
Upside: +263.01%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $10.51
Upside: +71.27%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $12.68
Upside: +215.46%